↓ Skip to main content

microRNAs as Potential Biomarkers in Adrenocortical Cancer: Progress and Challenges

Overview of attention for article published in Frontiers in endocrinology, January 2016
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • Above-average Attention Score compared to outputs of the same age and source (56th percentile)

Mentioned by

twitter
4 X users

Citations

dimensions_citation
48 Dimensions

Readers on

mendeley
57 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
microRNAs as Potential Biomarkers in Adrenocortical Cancer: Progress and Challenges
Published in
Frontiers in endocrinology, January 2016
DOI 10.3389/fendo.2015.00195
Pubmed ID
Authors

Nadia Cherradi

Abstract

Adrenocortical carcinoma (ACC) is a rare malignancy with poor prognosis and limited therapeutic options. Over the last decade, pan-genomic analyses of genetic and epigenetic alterations and genome-wide expression profile studies allowed major advances in the understanding of the molecular genetics of ACC. Besides the well-known dysfunctional molecular pathways in adrenocortical tumors, such as the IGF2 pathway, the Wnt pathway, and TP53, high-throughput technologies enabled a more comprehensive genomic characterization of adrenocortical cancer. Integration of expression profile data with exome sequencing, SNP array analysis, methylation, and microRNA (miRNA) profiling led to the identification of subgroups of malignant tumors with distinct molecular alterations and clinical outcomes. miRNAs post-transcriptionally silence their target gene expression either by degrading mRNA or by inhibiting translation. Although our knowledge of the contribution of deregulated miRNAs to the pathogenesis of ACC is still in its infancy, recent studies support their relevance in gene expression alterations in these tumors. Some miRNAs have been shown to carry potential diagnostic and prognostic values, while others may be good candidates for therapeutic interventions. With the emergence of disease-specific blood-borne miRNAs signatures, analyses of small cohorts of patients with ACC suggest that circulating miRNAs represent promising non-invasive biomarkers of malignancy or recurrence. However, some technical challenges still remain, and most of the miRNAs reported in the literature have not yet been validated in sufficiently powered and longitudinal studies. In this review, we discuss the current knowledge regarding the deregulation of tumor-associated and circulating miRNAs in ACC patients, while emphasizing their potential significance in pathogenic pathways in light of recent insights into the role of miRNAs in shaping the tumor microenvironment.

X Demographics

X Demographics

The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 57 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Brazil 1 2%
Unknown 56 98%

Demographic breakdown

Readers by professional status Count As %
Researcher 12 21%
Student > Ph. D. Student 12 21%
Student > Bachelor 10 18%
Student > Master 6 11%
Lecturer 2 4%
Other 6 11%
Unknown 9 16%
Readers by discipline Count As %
Medicine and Dentistry 13 23%
Agricultural and Biological Sciences 10 18%
Biochemistry, Genetics and Molecular Biology 10 18%
Pharmacology, Toxicology and Pharmaceutical Science 5 9%
Veterinary Science and Veterinary Medicine 2 4%
Other 4 7%
Unknown 13 23%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 03 February 2016.
All research outputs
#15,496,121
of 25,870,940 outputs
Outputs from Frontiers in endocrinology
#3,473
of 13,300 outputs
Outputs of similar age
#207,221
of 405,353 outputs
Outputs of similar age from Frontiers in endocrinology
#12
of 30 outputs
Altmetric has tracked 25,870,940 research outputs across all sources so far. This one is in the 38th percentile – i.e., 38% of other outputs scored the same or lower than it.
So far Altmetric has tracked 13,300 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.1. This one has gotten more attention than average, scoring higher than 72% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 405,353 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 47th percentile – i.e., 47% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 30 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 56% of its contemporaries.